241 related articles for article (PubMed ID: 32212972)
1. Update on urine as a biomarker in cancer: a necessary review of an old story.
Zhang W; Zhang XJ; Chao SY; Chen SJ; Zhang ZJ; Zhao J; Lv YN; Yao JJ; Bai YY
Expert Rev Mol Diagn; 2020 May; 20(5):477-488. PubMed ID: 32212972
[No Abstract] [Full Text] [Related]
2. Urinary Biomarkers in Tumors: An Overview.
Cimmino I; Bravaccini S; Cerchione C
Methods Mol Biol; 2021; 2292():3-15. PubMed ID: 33651347
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers.
Lopez-Beltran A; Cheng L; Gevaert T; Blanca A; Cimadamore A; Santoni M; Massari F; Scarpelli M; Raspollini MR; Montironi R
Expert Rev Mol Diagn; 2020 Feb; 20(2):231-243. PubMed ID: 31795775
[No Abstract] [Full Text] [Related]
4. Urine as a biological modality for colorectal cancer detection.
Chandrapalan S; Arasaradnam RP
Expert Rev Mol Diagn; 2020 May; 20(5):489-496. PubMed ID: 32130868
[No Abstract] [Full Text] [Related]
5. Urine biopsy technologies: Cancer and beyond.
Chen CK; Liao J; Li MS; Khoo BL
Theranostics; 2020; 10(17):7872-7888. PubMed ID: 32685026
[TBL] [Abstract][Full Text] [Related]
6. The potential of circulating cell free RNA as a biomarker in cancer.
Cheung KWE; Choi SR; Lee LTC; Lee NLE; Tsang HF; Cheng YT; Cho WCS; Wong EYL; Wong SCC
Expert Rev Mol Diagn; 2019 Jul; 19(7):579-590. PubMed ID: 31215265
[No Abstract] [Full Text] [Related]
7. Urinary microRNA and mRNA in Tumors.
Bandini E
Methods Mol Biol; 2021; 2292():57-72. PubMed ID: 33651352
[TBL] [Abstract][Full Text] [Related]
8. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
9. Exosomal biomarkers for cancer diagnosis and patient monitoring.
Makler A; Asghar W
Expert Rev Mol Diagn; 2020 Apr; 20(4):387-400. PubMed ID: 32067543
[No Abstract] [Full Text] [Related]
10. Liquid biopsy in the clinical management of bladder cancer: current status and future developments.
Kouba E; Lopez-Beltran A; Montironi R; Massari F; Huang K; Santoni M; Chovanec M; Cheng M; Scarpelli M; Zhang J; Cimadamore A; Cheng L
Expert Rev Mol Diagn; 2020 Feb; 20(2):255-264. PubMed ID: 31608720
[No Abstract] [Full Text] [Related]
11. Clinical utility of emerging biomarkers in prostate cancer liquid biopsies.
Boerrigter E; Groen LN; Van Erp NP; Verhaegh GW; Schalken JA
Expert Rev Mol Diagn; 2020 Feb; 20(2):219-230. PubMed ID: 31577907
[No Abstract] [Full Text] [Related]
12. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.
Lotan Y; Black PC; Caba L; Chang SS; Cookson MS; Daneshmand S; Kamat AM; McKiernan JM; Pruthi RS; Ritch CR; Steinberg GD; Svatek RS; Zwarthoff EC
Eur Urol Oncol; 2018 Aug; 1(3):223-230. PubMed ID: 31102625
[TBL] [Abstract][Full Text] [Related]
13. Cancer detection by native fluorescence of urine.
Masilamani V; Vijmasi T; Al Salhi M; Govindaraj K; Vijaya-Raghavan AP; Antonisamy B
J Biomed Opt; 2010; 15(5):057003. PubMed ID: 21054119
[TBL] [Abstract][Full Text] [Related]
14. DNA-Methylation-Based Detection of Urological Cancer in Urine: Overview of Biomarkers and Considerations on Biomarker Design, Source of DNA, and Detection Technologies.
Larsen LK; Lind GE; Guldberg P; Dahl C
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151158
[TBL] [Abstract][Full Text] [Related]
15. Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma.
Szarvas T; Nyirády P; Ogawa O; Furuya H; Rosser CJ; Kobayashi T
Methods Mol Biol; 2018; 1655():251-273. PubMed ID: 28889391
[TBL] [Abstract][Full Text] [Related]
16. Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers.
Lin SY; Linehan JA; Wilson TG; Hoon DSB
Eur Urol Focus; 2017 Apr; 3(2-3):265-272. PubMed ID: 28753876
[TBL] [Abstract][Full Text] [Related]
17. The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities.
Zaporozhchenko IA; Ponomaryova AA; Rykova EY; Laktionov PP
Expert Rev Mol Diagn; 2018 Feb; 18(2):133-145. PubMed ID: 29307231
[TBL] [Abstract][Full Text] [Related]
18. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
19. Cancer Biomarker Discovery for Precision Medicine: New Progress.
Zou J; Wang E
Curr Med Chem; 2019; 26(42):7655-7671. PubMed ID: 30027846
[TBL] [Abstract][Full Text] [Related]
20. Early Epigenetic Markers for Precision Medicine.
Dumitrescu RG
Methods Mol Biol; 2018; 1856():3-17. PubMed ID: 30178243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
